|
1
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamburg MA and Collins FS: The path to
personalized medicine. N Engl J Med. 363:301–304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ko AH and Tempero MA: Personalized
medicine for pancreatic cancer: A step in the right direction.
Gastroenterology. 136:43–45. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goonetilleke KS and Siriwardena AK:
Systematic review of carbohydrate antigen (CA 19–9) as a
biochemical marker in the diagnosis of pancreatic cancer. Eur J
Surg Oncol. 33:266–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kannagi R: Carbohydrate antigen sialyl
Lewis a-its pathophysiological significance and induction mechanism
in cancer progression. Chang Gung Med J. 30:189–209.
2007.PubMed/NCBI
|
|
8
|
Pleskow DK, Berger HJ, Gyves J, Allen E,
McLean A and Podolsky DK: Evaluation of a serologic marker, CA19-9,
in the diagnosis of pancreatic cancer. Ann Intern Med. 110:704–709.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schlieman MG, Ho HS and Bold RJ: Utility
of tumor markers in determining resectability of pancreatic cancer.
Arch Surg. 138:951–955. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tempero MA, Uchida E, Takasaki H, Burnett
DA, Steplewski Z and Pour PM: Relationship of carbohydrate antigen
19–9 and Lewis antigens in pancreatic cancer. Cancer Res.
47:5501–5503. 1987.PubMed/NCBI
|
|
11
|
Ferrone CR, Finkelstein DM, Thayer SP,
Muzikansky A, FernandezdelCastillo C and Warshaw AL: Perioperative
CA19-9 levels can predict stage and survival in patients with
resectable pancreatic adenocarcinoma. J Clin Oncol. 24:2897–2902.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Humphris JL, Chang DK, Johns AL, Scarlett
CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA,
et al: The prognostic and predictive value of serum CA19.9 in
pancreatic cancer. Ann Oncol. 23:1713–1722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kondo N, Murakami Y, Uemura K, Hayashidani
Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y,
et al: Prognostic impact of perioperative serum CA 19–9 levels in
patients with resectable pancreatic cancer. Ann Surg Oncol.
17:2321–2329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berger AC, Garcia M Jr, Hoffman JP, Regine
WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and
Willett CG: Postresection CA 19–9 predicts overall survival in
patients with pancreatic cancer treated with adjuvant
chemoradiation: A prospective validation by RTOG 9704. J Clin
Oncol. 26:5918–5922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berger AC, Meszoely IM, Ross EA, Watson JC
and Hoffman JP: Undetectable preoperative levels of serum CA 19–9
correlate with improved survival for patients with resectable
pancreatic adenocarcinoma. Ann Surg Oncol. 11:644–649. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Magnani JL, Steplewski Z, Koprowski H and
Ginsburg V: Identification of the gastrointestinal and pancreatic
cancer-associated antigen detected by monoclonal antibody 19–9 in
the sera of patients as a mucin. Cancer Res. 43:5489–5492.
1983.PubMed/NCBI
|
|
18
|
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng
H, Lu Y, Long J, Liu L, Xu J, et al: Optimize CA19-9 in detecting
pancreatic cancer by Lewis and Secretor genotyping. Pancreatology.
pii:S1424–3903. 2016.(Epub ahead of print).
|
|
19
|
Takada A, Ohmori K, Yoneda T, Tsuyuoka K,
Hasegawa A, Kiso M and Kannagi R: Contribution of carbohydrate
antigens sialyl Lewis A and sialyl Lewis X to adhesion of human
cancer cells to vascular endothelium. Cancer Res. 53:354–361.
1993.PubMed/NCBI
|
|
20
|
Aubert M, Panicot L, Crotte C, Gibier P,
Lombardo D, Sadoulet MO and Mas E: Restoration of alpha(1,2)
fucosyltransferase activity decreases adhesive and metastatic
properties of human pancreatic cancer cells. Cancer Res.
60:1449–1456. 2000.PubMed/NCBI
|
|
21
|
Aubert M, PanicotDubois L, Crotte C,
Sbarra V, Lombardo D, Sadoulet MO and Mas E: Peritoneal
colonization by human pancreatic cancer cells is inhibited by
antisense FUT3 sequence. Int J Cancer. 88:558–565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iwai K, Ishikura H, Kaji M, Sugiura H,
Ishizu A, Takahashi C, Kato H, Tanabe T and Yoshiki T: Importance
of E-selectin (ELAM-1) and sialyl Lewis(a) in the adhesion of
pancreatic carcinoma cells to activated endothelium. Int J Cancer.
54:972–977. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hartwig W, Strobel O, Hinz U, Fritz S,
Hackert T, Roth C, Büchler MW and Werner J: CA19-9 in potentially
resectable pancreatic cancer: Perspective to Adjust Surgical and
Perioperative Therapy. Ann Surg Oncol. 20:2188–2196. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Björk S, Breimer ME, Hansson GC, Karlsson
KA and Leffler H: Structures of blood group glycosphingolipids of
human small intestine. A relation between the expression of
fucolipids of epithelial cells and the ABO, Le and Se phenotype of
the donor. J Biol Chem. 262:6758–6765. 1987.PubMed/NCBI
|
|
25
|
Hamada E, Taniguchi T, Baba S and Maekawa
M: Investigation of unexpected serum CA19-9 elevation in
Lewis-negative cancer patients. Ann Clin Biochem. 49:266–272. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirano K, Kawa S, Oguchi H, Kobayashi T,
Yonekura H, Ogata H and Homma T: Loss of Lewis antigen expression
on erythrocytes in some cancer patients with high serum CA19-9
levels. J Natl Cancer Inst. 79:1261–1268. 1987.PubMed/NCBI
|
|
27
|
Orntoft TF, Holmes EH, Johnson P, Hakomori
S and Clausen H: Differential tissue expression of the Lewis blood
group antigens: Enzymatic, immunohistologic, and immunochemical
evidence for Lewis a and b antigen expression in Le(a-b-)
individuals. Blood. 77:1389–1396. 1991.PubMed/NCBI
|
